/NOT FOR DISTRIBUTION TO UNITED
STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN
THE UNITED STATES/
CALGARY, June 21, 2017 /CNW/ - Resverlogix Corp.
("Resverlogix" or the "Company") (TSX:RVX) today confirmed, as
announced on June 20, 2017, that its
previously-announced equity offering closed as previously scheduled
on June 20, 2017, issuing a total of
$10 million of its equity units. A
June 20, 2017 TSX Trader Note stated
that the closing had been delayed. A second June 20, 2017 TSX Trader Note published shortly
thereafter stated that the equity offering had closed, however
certain outlets did not communicate the second TSX Trader Note to
their users.
About Resverlogix
Resverlogix is developing apabetalone (RVX-208), a
first-in-class, small molecule that is a selective BET (bromodomain
and extra-terminal) inhibitor. BET bromodomain inhibition is an
epigenetic mechanism that can regulate disease-causing genes.
Apabetalone is the first and only BET inhibitor selective for the
second bromodomain (BD2) within the BET protein called BRD4. This
selective inhibition of apabetalone on BD2 produces a specific set
of biological effects with potentially important benefits for
patients with high-risk cardiovascular disease (CVD), diabetes
mellitus (DM), chronic kidney disease, dialysis, Alzheimer's
disease, Fabry disease, other orphan diseases, and peripheral
artery disease, while maintaining a well described safety profile.
Apabetalone is the only selective BET bromodomain inhibitor in
human clinical trials. Apabetalone is currently being studied in a
Phase 3 trial, BETonMACE, in high-risk CVD patients with type 2 DM
and low high-density lipoprotein (HDL), and is expected to be
initiated in a Phase 2a kidney dialysis trial designed to evaluate
biomarker changes and safety parameters in up to 30 patients with
end-stage renal disease treated with hemodialysis.
Resverlogix common shares and warrants trade on the Toronto
Stock Exchange (TSX:RVX and RVX.WT).
Follow us on Twitter:
@Resverlogix_RVX (https://twitter.com/resverlogix_rvx), or on
our blog at http://www.resverlogix.com/blog
For further information please contact:
Investor Relations
Email: ir@resverlogix.com
Phone: 403-254-9252
Or visit our website: www.resverlogix.com
This news release may contain certain forward-looking
information as defined under applicable Canadian securities
legislation, that are not based on historical fact, including
without limitation statements containing the words "believes",
"anticipates", "plans", "intends", "will", "should", "expects",
"continue", "estimate", "forecasts" and other similar expressions.
In particular, this news release includes forward looking
information relating to the potential role of apabetalone in the
treatment of CVD, DM, chronic kidney disease, end-stage renal
disease treated with hemodialysis, Alzheimer's disease, Fabry
disease, and Orphan diseases. Our actual results, events or
developments could be materially different from those expressed or
implied by these forward-looking statements. We can give no
assurance that any of the events or expectations will occur or be
realized. By their nature, forward-looking statements are subject
to numerous assumptions and risk factors including those discussed
in our Annual Information Form and most recent MD&A which are
incorporated herein by reference and are available through SEDAR at
www.sedar.com. The forward-looking statements contained in this
news release are expressly qualified by this cautionary statement
and are made as of the date hereof. The Company disclaims any
intention and has no obligation or responsibility, except as
required by law, to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
SOURCE Resverlogix Corp.